Mangoceuticals, Common Stock Stock Performance
| MGRX Stock | 2.47 0.34 12.10% |
On a scale of 0 to 100, Mangoceuticals, Common holds a performance score of 3. The company secures a Beta (Market Risk) of 0.69, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Mangoceuticals, Common's returns are expected to increase less than the market. However, during the bear market, the loss of holding Mangoceuticals, Common is expected to be smaller as well. Please check Mangoceuticals, Common's value at risk, as well as the relationship between the kurtosis and price action indicator , to make a quick decision on whether Mangoceuticals, Common's current price movements will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Mangoceuticals, Common Stock are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Mangoceuticals, Common showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (12.10) | Five Day Return (43.35) | Year To Date Return (0.80) | Ten Year Return (95.88) | All Time Return (95.88) |
Last Split Factor 1:15 | Last Split Date 2024-10-16 |
1 | Insider Trading | 01/14/2025 |
2 | Symbol Lookup | 02/03/2025 |
3 | Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Coh... | 02/06/2025 |
4 | Acquisition by Dalessio Lorraine Pamela of 100000 shares of Mangoceuticals, Common subject to Rule 16b-3 | 02/07/2025 |
5 | Mangoceuticals Inc. issues stock for consulting services - Investing.com | 02/19/2025 |
6 | Mangoceuticals Announces the Launch of PeachesRx - a Womens Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments | 02/20/2025 |
7 | Mangoceuticals Expands into 33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol in ... | 03/25/2025 |
| Begin Period Cash Flow | 739 K |
Mangoceuticals, |
Mangoceuticals, Common Relative Risk vs. Return Landscape
If you would invest 260.00 in Mangoceuticals, Common Stock on December 27, 2024 and sell it today you would lose (13.00) from holding Mangoceuticals, Common Stock or give up 5.0% of portfolio value over 90 days. Mangoceuticals, Common Stock is currently generating 0.3902% in daily expected returns and assumes 9.3369% risk (volatility on return distribution) over the 90 days horizon. In different words, 83% of stocks are less volatile than Mangoceuticals,, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mangoceuticals, Common Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mangoceuticals, Common's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mangoceuticals, Common Stock, and traders can use it to determine the average amount a Mangoceuticals, Common's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0418
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MGRX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 9.34 actual daily | 83 83% of assets are less volatile |
Expected Return
| 0.39 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Mangoceuticals, Common is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mangoceuticals, Common by adding it to a well-diversified portfolio.
Mangoceuticals, Common Fundamentals Growth
Mangoceuticals, Stock prices reflect investors' perceptions of the future prospects and financial health of Mangoceuticals, Common, and Mangoceuticals, Common fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mangoceuticals, Stock performance.
| Return On Equity | -1.18 | ||||
| Return On Asset | -0.63 | ||||
| Operating Margin | (22.65) % | ||||
| Current Valuation | 12.92 M | ||||
| Shares Outstanding | 4.97 M | ||||
| Price To Book | 0.92 X | ||||
| Price To Sales | 22.67 X | ||||
| Revenue | 473.26 K | ||||
| Gross Profit | 379.96 K | ||||
| EBITDA | (7.97 M) | ||||
| Net Income | (8.71 M) | ||||
| Total Debt | 214.96 K | ||||
| Book Value Per Share | 4.30 X | ||||
| Cash Flow From Operations | (4.86 M) | ||||
| Earnings Per Share | (4.84) X | ||||
| Market Capitalization | 13.96 M | ||||
| Total Asset | 15.37 M | ||||
| Retained Earnings | (20.81 M) | ||||
| Working Capital | (1.35 M) | ||||
About Mangoceuticals, Common Performance
Evaluating Mangoceuticals, Common's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Mangoceuticals, Common has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mangoceuticals, Common has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 20.26 | 18.01 | |
| Return On Tangible Assets | (63.14) | (59.98) | |
| Return On Capital Employed | (0.57) | (0.60) | |
| Return On Assets | (0.57) | (0.59) | |
| Return On Equity | (0.62) | (0.66) |
Things to note about Mangoceuticals, Common performance evaluation
Checking the ongoing alerts about Mangoceuticals, Common for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mangoceuticals, Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mangoceuticals, Common had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 473.26 K. Net Loss for the year was (8.71 M) with profit before overhead, payroll, taxes, and interest of 379.96 K. | |
| Mangoceuticals, Common generates negative cash flow from operations | |
| Mangoceuticals, Common has a poor financial position based on the latest SEC disclosures | |
| About 36.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Mangoceuticals Expands into 33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol in the USA and Canada |
- Analyzing Mangoceuticals, Common's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mangoceuticals, Common's stock is overvalued or undervalued compared to its peers.
- Examining Mangoceuticals, Common's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mangoceuticals, Common's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mangoceuticals, Common's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mangoceuticals, Common's stock. These opinions can provide insight into Mangoceuticals, Common's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Mangoceuticals, Stock Analysis
When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.